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Thrombin has a bimodal effect on glioma cell growth
H Schafberg, G Nowak and R Kaufmann
Max Planck Gesellschaft, Research Unit 'Pharmacological Hemostaseology' at the Friedrich Schiller University Jena, Drackendorfer Str. 1, Jena, Germany
Summary Using rat glioma C6 cells as a model, we have found a bimodal effect of a-thrombin on cell growth. In C6 cells treated with
a-thrombin at concentrations from 0.02 nm to 1.0 nm, inhibition of cell proliferation was noted. Because the thrombin receptor agonist peptide
TRAP-6 also induced inhibition of cell proliferation and the thrombin receptor antagonist peptide Ti prevented the inhibitory effect of a-
thrombin on C6 glioma cell growth, thrombin receptor involvement in antiproliferative action of a-thrombin in C6 glioma cells is highly likely.
However, stimulation of cell proliferation observed when C6 cells were treated with a-thrombin at higher doses (> 1.0 nM) seems to be
mediated by as yet undefined thrombin receptor-independent biochemical mechanisms.
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Thrombin evokes biological responses from a variety of cells,
including platelets (Bemdt and Philipps, 1981), fibroblasts,
vascular smooth muscle cells (Glenn et al, 1980) and monocytes
(Bar-Shavit et al, 1983). These effects are known to be mediated
by the activation of thrombin receptors in these cells. The
thrombin receptor belongs to the family of G-protein-coupled
receptors. Thrombin binds to this receptor and cleaves it in the
amino-terminal portion. This cleavage event unmasks a new
amino terminus that then functions as a 'tethered peptide ligand',
binding to the thrombin receptor in specific regions to cause
receptor activation. Synthetic peptides of 5-14 amino acids
(thrombin receptor-activating peptides, TRAPs), corresponding to
the tethered ligand sequence, were found to be agonists for
receptor activation (Vu et al, 1991; Nanevicz et al, 1995).
Thrombin is a well-studied mitogen for a variety of cell types
(Chen and Buchanan, 1975; Camey et al, 1985) and it seems to
play a role in tumour growth (Zacharski, 1987; Nierodzik et al,
1992). Recently, the presence of 'tethered ligand' thrombin
receptor in carcinosarcoma and melanoma cells has been shown,
and its biological function has been suggested (Wojtukiewicz et al,
1995). However, the role of thrombin and the 'tethered ligand'
thrombin receptor in tumour cell metabolism is still undefined.
Rat glioma C6 cells, a widely used model in neurobiological
studies, are known to respond to thrombin with morphological
changes (Tas and Koschel, 1990), and thrombin receptor-mediated
transmembrane signalling has been investigated (Turner et al,
1994; Czubayko and Reiser, 1995; Kaufmann et al, 1996).
Moreover, this tumour cell line has been frequently used in the
investigation ofglioma cell growth (Barg et al, 1994; Strawn et al,
1994; Takano et al, 1994).
In this study, we assessed the effects ofa-thrombin on cellprolif-
eration in rat glioma C6 cells by the estimation of [3H]thymidine
incorporation and the increase in cell number. The results demon-
strate that a-thrombin has opposite effects on glioma cell growth.
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MATERIALS AND METHODS
Human a-thrombin (3700 NIH-U mg-' protein) was purchased from
Sigma Chemicals (Deisenhofen, Germany), [methyl-3H]thymidine
(79 Ci mmol-') fromAmersham Buchler(Braunschweig, Germany),
Hirudin (HBW 023) from Hoechst AG (Frankfurt, Germany) and
the thrombin receptor antagonist (Met-Ser-Arg-Pro-Ala-Cys-Pro-
Asn-Asp-Lys-Tyr-Glu, peptide TI) was purchased from Neosystem
(Strasbourg, France).
The rat glioma cell line C6 was obtained from American Type
Culture Collection (Rockville, MD, USA).
Peptide synthesis
TRAP-6 (Ser-Phe-Leu-Leu-Arg-Asn) was synthesized by Dr Peter
Henklein, Institute of Biochemistry, Charite, Berlin, by fmoc
strategy on an ABI-Peptide-Synthesizer 433A. Protection of side
chains was carried out for Ser as tert-but, for Asn as trt, for Asp
and Glu as 0-but, for Lys as boc.
Cell culture
Rat glioma C6 cells were grown as monolayer cultures in Ham's
F-12 medium supplemented with 2.5% fetal calf serum (FCS) and
15% horse serum. Cells were routinely cultured at 37°C in a
humidified atmosphere of5% carbon dioxide. The culture medium
was changed every 2-3 days.
Measurement of [3H]thymidine incorporation
C6 cells were plated in 96-well plates in Ham's-F12 medium
containing 15% horse serum and 2.5% FCS for48 h. Afterincuba-
tion in serum-free medium for 24 h, the cells were treated for a
further 24 h with test agents and [methyl-3H]thymidine (0.05 pCi
per well). Then the cells were treated with trichloroacetic acid
(10%) for 15 min on ice and rinsed twice with ice-cold phosphate-
buffered saline (PBS). After treatment with ice-cold methanol, the
cells were lysed with sodium hydroxide and counted by liquid
scintillation (Wallac 1409 Liquid Scintillation Counter).
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Figure 1 [3H]thymidine incorporation into DNA in C6 rat glioma cells
exposed to a-thrombin. Cells were stimulated with a-thrombin for 24 h.
Estimation of [3H]thymidine incorporation was performed as described in
Materials and methods. Results are the means ± s.e. (n = 24) from a
representative experiment (*P < 0.02, compared with the control; Student's
t-test). Similar results were obtained in the other two experiments. Variation
between experiments was less than 10%. Control, non-stimulated C6 cells.
Data are presented as a percentage of control (7580 ± 380 d.p.m.)
Cell growth assay
C6 glioma cells were grown on CELLocate coverslips (alphabeti-
cally labelled squares, square size 175 ,um, Eppendorf) placed in
six-well plates in Ham's F12 medium containing 15% horse serum
and 2.5% FCS for48 h. After incubation in serum-free medium for
24 h, a baseline cell count was performed using an Axiovert 135
microscope (Carl Zeiss). For this purpose, all the squares of the
CELLocate growth chamber were counted. Then, the cells were
treated for a further 48 h with test agents. After this period, cells
were counted again and the increase in cell number was deter-
mined. Cell viability was estimated by trypan blue exclusion.
RESULTS
First, we investigated the effects of a-thrombin and thrombin
receptor agonist TRAP-6 on DNA synthesis in C6 glioma cells. a-
thrombin was shown to influence DNA synthesis in rat glioma C6
cells dose dependently. As shown in Figure 1, the application of a-
thrombin at concentrations < 1.0 nm resulted in the inhibition of
[3H]thymidine incorporation. The effect was obtained with a
threshold concentration of 0.02 nM a-thrombin (Figure 1).
Maximal inhibition was seen after exposure of C6 glioma cells
with 0.07 nM a-thrombin (Figure 1). As further shown in Figure 1,
at concentrations > 1.0 nM, a-thrombin stimulated DNA synthesis
in C6 glioma cells.
In a further series ofexperiments, we investigated the participa-
tion ofthrombin receptor activation in a-thrombin-induced effects
on [3H]thymidine incorporation in C6 cells. First, TRAP-6 was
shown dose dependently to induce inhibition of [3H]thymidine
incorporation in C6 glioma cells (Figure 2). Then, we investigated
the effect of the thrombin receptor antagonist Met-Ser-Arg-Pro-
Ala-Cys-Pro-Asn-Asp-Lys-Tyr-Glu (peptide T1) on a-thrombin-
and TRAP-induced effects on DNA synthesis in C6 cells. When
C6 cells were preincubated with the thrombin receptor antagonist
for 30 min, the inhibitory action of a-thrombin on DNA synthesis
in C6 glioma cells could be completely blocked (Figure 3).
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Figure 2 [3H]thymidine incorporation into DNA in C6 rat glioma cells
exposed to TRAP-6. Cells were stimulated with TRAP-6 for 24 h and
[3H]thymidine incorporation was measured as descrbed in Matenals and
methods. Results are the means ± s.e. (n= 24) from a representative
experiment (*P< 0.05, compared with the control; Student's t-test). Similar
results were obtained in asecond series of experiments with variation of less
than 10%. Control, non-stimulated C6 cells. Data are presented as a
percentage of control (7100 ± 426 d.p.m.)
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Figure 3 Effect of the thrombin receptor antagonist peptide Ti on
[3H]thymidine incorporation induced by a-thrombin orTRAP-6 in C6 glioma
cells. C6 cells were preincubated with peptide Ti (1.0 gM) for 30 min and
stimulated with a-thrombin (0.1 nM) or TRAP-6 (10 gM) for 24 h. [3H]thymidine
incorporation was measured as described in Materials and methods. Data
represent the means ± s.e. (n = 24) from a representative experiment-
(*P < 0.02, compared with both the control and cells pretreated with peptide
T1; Student's t-test). Similar results were obtained in a second series of
experiments with variation of less than 10%. Control, non-stimulated C6
cells. Data are presented as a percentage of control (7270 ± 365 d.p.m.)
However, peptide TI failed to prevent the increased [3H]thymidine
incorporation in C6 cells noted when C6 glioma cells were stimu-
lated with a-thrombin at concentrations > 1.0 nm (Figure 3). In
addition, the thrombin receptor antagonist peptide TI (1.0 ,UM)
could prevent the TRAP-6 induced effects on [3H]thymidine incor-
poration in C6 glioma cells (Figure 3).
Moreover, in C6 cells treated with the thrombin inhibitor
hirudin (50 nM) thrombin-induced inhibition or stimulation of
DNA synthesis could no longer be observed. But hirudin was
unable to abrogate the TRAP-6 induced inhibition of [3H]thymi-
dine incorporation in C6 glioma cells (data not shown).
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Figure 4 Effect of a-thrombin and TRAP-6 on the proliferation of C6 glioma
cells. Experiments were performed as described in Materials and methods.
Values represent the means ± s.e. percentage increase in cell number of at
least five independent experiments, each performed in duplicate (*P < 0.05,
compared with both the control and cells pretreated with peptide T1;
Student's t-test). Control, non-stimulated C6 cells. Data are presented as a
percentage of control (cell number = 740 ± 26)
In a further experimental setup, we assessed the effect of a-
thrombin on cell proliferation by determining the increase in cell
number. The application of a-thrombin at concentrations from
0.02 nm to 1.0 nm significantly reduced the proliferation of C6
cells as shown inFigure 4 forthe treatment ofC6 cells with0.1 nM
a-thrombin. This effect could be completely blocked by peptide
TI (Figure 4). In contrast to this, higher concentrations of a-
thrombin (> 1.0nM) enhanced C6 cell proliferation, compared
with non-stimulated C6 cells. Figure 4 also shows that peptide TI
was unable to abrogate this positive effect ofa-thrombin on prolif-
eration in C6 cells. Moreover, TRAP-6 induced a significant
decrease in cell proliferation compared with non-stimulated C6
cells, as shown forC6 cells treated with 10 ,UM TRAP-6 (Figure 4).
Preincubation of C6 cells with peptide TI (1.0 ,IM) for 30 min
prevented the TRAP-6-induced inhibitory effect of the prolifera-
tion in C6 cells (Figure 4).
DISCUSSION
Rat glioma C6 cells are a widely used model in neurobiology, but
this tumour cell line may also be used as a model in studying brain
cancer.
In this study, we investigated the effect of a-thrombin on cell
proliferation in C6 cells by measurement of DNA synthesis and
counting ofcell number. Inhibition of[3H]thymidine incorporation
and a significantly reduced cell number were noted when C6 cells
were treated with low doses of a-thrombin or TRAP-6. Together
with the finding that peptide TI completely blocked the a-
thrombin and TRAP-6-induced effect on decreased [3H]thymidine
incorporation and cell number in C6 glioma cells it seems to be
very likely that a 'tethered ligand' thrombin receptor is involved in
the inhibitory effects ofthrombin on cell proliferation in C6 cells.
However, other biochemical mechanisms seem to contribute to the
proliferative effect at higher doses of thrombin (> 1.0 nM) in C6
cells. This suggestion was supported by the observation that the
thrombin receptor peptide Ti was unable to prevent the effects of
thrombin at higher doses on cell proliferation in C6 cells.
Our results demonstrate for the first time a bimodal role of a-
thrombin as both a negative and apositive regulator oftumour cell
growth. Therefore, C6 cells seem tobe avery interesting model for
studying the function of thrombin in brain tumour growth. In C6
cells, the antiproliferative action of a-thrombin at lower doses
seems to be mediated by the 'tethered ligand' thrombin receptor.
This part of a-thrombin action in C6 glioma is in line with the
situation found in megakaryocytic cells, in which involvement of
thrombin receptor activation in an antiproliferative action of
thrombin has been demonstrated by Plantieret al (1994). However,
there must be other mechanisms that contribute to the increase in
[3H]thymidine incorporation and enhanced cell number in C6
glioma observed when a-thrombin was added at concentrations
> 1.0 nm. We found in our investigations that the thrombin
inhibitorhirudin blocked both thethrombin-induced inhibition and
stimulation of [3H]thymidine incorporation in C6 glioma cells.
Because hirudin is known to bind very tightly not only to the
catalytic site, but also to other sites outside the active site (exosite
I, substrate recognition site, Rydel et al, 1990) in the thrombin
molecule, involvement of these non-catalytic binding sites in the
proliferative action of a-thrombin in C6 glioma cells seems to be
possible. Moreover, it is known that the non-catalytic action of
thrombin may result in enhanced mitogenesis in different cell
types (Hollenberg, 1996) and thrombin was shown to induce
growth of the endothelial HUVEC cell line via dual-signalling
pathways, with one of them seemingly being mediated by non-
proteolytic actions (Herbert et al, 1994).
Further investigations are in progress to clarify whether such
non-proteolytic processes participate in the proliferative effects of
thrombin in C6 rat glioma cells.
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